Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Younger newly diagnosed mantle cell lymphoma treated with alternating EPOCH±rituximab and DHAP±rituximab followed by ASCT
ChiCTR-OPC-15007260Phase 3Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jan 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of rituximab, etoposide, prednisone, vincristine, cyclophosphamide and 4 more in mantle cell lymphoma (MCL), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: progression-free survival and overall survival. Planned start Jan 2016; status: not yet recruiting.
02
Drugs
rituximabetoposideprednisonevincristinecyclophosphamide
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on ChiCTR-OPC-15007260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-15007260.